MME DANIELLE BITTON-REZLAN

Rhumatologue

📍 BRY SUR MARNE (94)LibéralRPPS 10001226975

✨ Profil synthétique

IA · 24/05/2026

Mme Danielle Bitton-Rezlan est une rhumatologue exerçant à Bry sur Marne. Ses publications sur PubMed couvrent divers aspects de la rhumatologie, notamment les pathologies liées à la santé mentale et la fatigue. Elle a également participé à des essais cliniques, des revues générales et des études épidémiologiques.

Expertises présumées

Fatigue chronique
Santé mentale en rhumatologie
Essais cliniques en rhumatologie
Épidémiologie des maladies rhumatismales
Revue systématique de la littérature médicale
Méta-analyse en rhumatologie
Gestion de la santé mentale en patientèle rhumatologique

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR DANIELLE BITTON-REZLAN
5 RUE DE LA REPUBLIQUE, 94360 BRY SUR MARNE
☎ 0145160101Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

C-Reactive Protein (CRP) and its Association with Periodontal Disease: A Brief Review

Journal of clinical and diagnostic research : JCDR · 2014

📚 96 citations🎯 RCR 4.42Top 9% NIH🔓 Open Access📄 PDF gratuit ↗

The effect of sleep disturbances and internet addiction on suicidal ideation among adolescents in the presence of depressive symptoms

Psychiatry research · 2018

📚 60 citations🎯 RCR 4.60Top 9% NIH

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

BMC infectious diseases · 2021

📚 50 citations🎯 RCR 2.39Top 22% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care.

Cookies & analyse de trafic

MME DANIELLE BITTON-REZLAN

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (20) — classées par pathologie

Santé mentale / fatigue4

Transversal4

Case report / série3

Essai clinique3

Revue générale3

Épidémiologie & registres2

Revue / méta-analyse2

Biomarqueurs / Auto-Ac1

csDMARDs1

Goutte1

Lupus1

Partager cette fiche